BioCentury
ARTICLE | Clinical News

Zydelig idelalisib: Phase III data

November 23, 2015 8:00 AM UTC

Gilead said the double-blind, placebo-controlled, U.S. Phase III Study 115 trial in 416 previously treated patients with relapsed CLL will be unblinded early after a pre-defined interim analysis showe...